参考文献

参考文献

［1］Cunningham D，Starling N，Rao S，et al.Capecitabine and oxaliplatin for advanced esophagogastric cancer［J］.N Engl J Med，2008358（18）：36-46.

［2］Kang YK，Kang WK，Shin DB，et al.Capecitabine／cisplatin versus 5-fluorouracil／cisplatin as first-line therapy patients with advanced gastric cancer：a randomized phaseⅢnoninferiority trial［J］.Ann Oncol，2009，20（4）：666-673.

［3］Van Cutsem E，Moiseyenko VM，Tjulandin S，et al.PhaseⅢstudy of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer：a report of the V325 Study Group［J］.J Clin Oncol，2006，24（31）：4991-4997.

［4］Wang J，Xu R，Li J，et al.Randomized multicenter phaseⅢstudy of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer［J］.Gastric Cancer，2016，19（1）：234-244.

［5］Koizumi W，Narahara H，Hara T，et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer（SPIRITS trial）：a phase Ill trial［J］.Lancet Oncol，2008，9（3）：215-221.

［6］Ajani JA，Rodriguez W，Bodoky G，et al. Multicenter phaseⅢcomparison of cisplatin／S-1 with cisplatin／infusional fluorouracil in advanced gastric or gastro-esophageal adenocarcinoma study：the FLAGS trial［J］.J Clin Oncol，2010，28（9）：1547-1553.

［7］Luo HY，Xu RH，Wang F，et al.PhaseⅡtrial of XELOX as first-line treatment for patients with advanced gastric cancer［J］.Chemotherapy，2010，56（2）：94-100.

［8］He MM，Wang F，Xu RH，et al.PhaseⅡclinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer［J］.Cancer Sci，2018，109（11）：3575-3582.

［9］Bang YJ，Van Cutsem E，Feyereislova A，et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER-2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase3，open-label，randomized controlled trial［J］.Lancet，2010，376（9742）：687-697.

［10］中国临床肿瘤学会抗肿瘤药物安全管理专家委员会（ASMC），中国抗癌协会胃癌专业委员会，中国抗癌协会肿瘤病理专业委员会.HER-2阳性晚期胃癌分子靶向治疗的中国专家共识（2016）［J］.临床肿瘤学杂志，2016，21（9）：831-839.

［11］Satoh T，Xu RH，Chung HC，et al.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER-2-amplified advanced gastric cancer in Asian populations：TyTAN-a randomized，phaseⅢstudy［J］.J Clin Oncol，2014，32（19）：2039-2049.

［12］Hecht JR，Bang YJ，Qin SK，et al.Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor2-positive advanced or metastatic gastric，esophageal，or gastroesophageal adenocarcinoma：TRIO-013／LOGiC-a randomized phaseⅢtrial［J］.J Clin Oncol，2016，34（5）：443-451.

［13］Shinohara T，Maeda Y，HamadaT，et al.Survival benefit of surgical treatment for liver metastases from gastric cancer［J］.J Gastrointest Surg，2015，19（6）：1043-1051.

［14］Markar SR，Mikhail S，Malietzis G，et al. Influence of surgical resection of hepatic metastases from gastric adenocarcinoma on longterm survival：systematic review and pooled analysis［J］.Ann Surg，2016，263（6）：1092-1101.

［15］Zhou F，Yu XL，Liang P，et al.Microwave ablation is effective against liver metastases from gastric adenocarcinoma［J］.Int J Hyperthermia，2017，33（7）：830-835.(https://www.daowen.com)

［16］Hwang JE，Kim SH，Jin J，et al. Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer［J］.Clin Exp Metastasis，2014，31（1）：25-32.

［17］Oki E，Tokunaga S，Emi Y，et al. Surgical treatment of liver metastasis of gastric cancer：a retrospective multicenter cohort study（KSCC1302）［J］.Gastric cancer，2016，19（3）：968-976.

［18］Jiang H，Li Q，Yu S，et al.Impact of HER-2 expression on outcome in gastric cancer patients withliver metastasis［J］.Clin Transl Oncol，2017，19（2）：197-203.

［19］Tang K，Liu Y，Dong L，et al.Influence of thermal ablation of hepatic metastases from gastric adenocarcinoma on long-term survival：Systematic review and pooled analysis［J］. Medicine（Baltimore），2018，97（49）：e13525.

［20］Ford HE，Marshall A，Bridgewater JA，et al.Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma（COUGAR-02）：an open-label，phase 3 randomised controlled trial［J］.Lancet Oncol，2014，15（1）：78-86.

［21］Wilke H，Muro K，Van Cutsem E，et al.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma（RAINBOW）：a double-blind，randomised phase 3 trial［J］.Lancet Oncol，2014，15（11）：1224-1235.

［22］Hironaka S，Ueda S，Yasui H，et al.Randomized，open-label，phaseⅢstudy comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum：WJOG 4007 trial［J］.J Clin Oncol，2013，31（35）：4438-4444.

［23］Sym SJ，Hong J，Park J，et al.A randomized phaseⅡstudy of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil／leucovorin（mFOLFIRI）in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy［J］.Cancer Chemother Pharmacol，2013，71（2）：481-488.

［24］Thuss-Patience PC，Kretzschmar A，Bichev D，et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomized phaseⅢstudy of the Arbeitsgemeinschaft internistische Onkologie（AIO） ［J］. Eur J Cancer，2011，47（15）：2306-2314.

［25］Fuchs CS，Moore MR，Harker G，et al.PhaseⅢcomparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer［J］.J Clin Oncol，2003，21（5）：807-814.

［26］Sym SJ，Ryu MH，Lee JL，et al.Salvage chemotherapy with biweekly irinotecan，plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine，platinum，and taxane［J］.Am J Clin Oncol，2008，31（2）：151-156.

［27］Shitara K，Doi T，Dvorkin M，et al. Trifluridine／tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer（TAGS）：a randomised，double-blind，placebo-controlled，phase 3 trial［J］.Lancet Oncol，2018，19（11）：1437-1448.

［28］Le DT，Uram JN，Wang H，et al.PD-1 Blockade in Tumors with Mismatch-Repair Deficiency［J］.N Engl J Med，2015，372（26）：2509-2520.

［29］Le DT，Durham JN，Smith KN，et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade［J］.Science，2017，357（6349）：409-413.